Sign up
Pharma Capital

SkinBioTherapeutics surges on cream formulation success

The cream has been formulated to contain SkinBioTherapeutics' proprietary technology, SkinBiotix; tests have proved the cream formulation retains the same beneficial properties as the original technology
Woman applying make-up
SkinBioTherapeutics' technology uses extracts of probiotic bacteria that protect the skin from infection by out-competing harmful pathogens

Skin health specialist SkinBioTherapeutics PLC (LON:SBTX) said the 'cream' formulation of its SkinBiotix technology has passed effectiveness studies in models of skin.

The cream formulation will now undergo further testing for stability in the coming weeks.

WATCH: Industry heavyweights 'sitting up and taking notice' of SkinBio's technology

The company's SkinBiotix platform uses extracts of probiotic bacteria for application to the skin and SkinBio has shown in skin models that its technology can improve the skin's barrier function.

The data from the tests showed a direct correlation between the amount of SkinBiotix within the cream and the level present of a specific protein essential to the barrier function of the skin. Work on creating skin lotion and gel formulations is ongoing.

"The incorporation of our SkinBiotix technology into an effective cream formulation is a major milestone in the development of products for the cosmetic market and, subject to stability testing, allows us to create formulations for our human study later this year," said Dr Catherine O'Neill, the chief executive officer of SkinBioTherapeutics.

Shares in SkinBio opened 6.4% higher at 10.375p.

Why Invest In SkinBioTherapeutics PLC? Read More Here

Register here to be notified of future SBTX Company articles
View full SBTX profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.